Vectofusin®-1 130-111-163 from Miltenyi Biotec

(1) Metabolically and epigenetically reprogrammed splenic TRNP1hiCD8+ T cells exacerbate liver fibrosisNat GenetJuly 8, 2026Liyuan Zhang, Yahui Wang, Kai Wei, Wen Nie, Yayuan Feng, Zhiwen Shi, Hongmei Xiao, Weifen Xie, Yong Lin, Xin Zeng, et al.multiplicity of infection of 20 in medium containing 100 ng ml−1 IL-2 and 10 μg ml−1 Vectofusin-1 (130-111-163, Miltenyi Biotec). Transfected cells were cultured in the medium containing IL-2 (100 ng/ml) for 2 days,

(2) A Scalable Lentiviral Workflow for Laboratory-Scale Generation of BCMA/GPRC5D Co-Transduced CAR-T Cells in Multiple MyelomaCurr Issues Mol BiolJune 30, 2026Ewa Nowak, Emilia Morawiec, Adam Pudełko, Agnieszka Polak, Mateusz Broncel, Daria Matczyńska, Dawid Zamojski, Michał Czerwinski, Anna Bednarska-Czerwińskain the presence of Vectofusin-1 (Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany; cat. no. 130-111-163; 10 µL/mL). Spinoculation was performed at 400× g for 1 h at 32 °C, followed by incubation at 37 °C

(3) BaEV-pseudotyped lentiviral vectors enable stable CAR expression and cytotoxic function in NK cellsPLoS OneMay 21, 2026Minji Park, Yuree Lim, Yujung Jo, Dong-Hyeon Jo, Sang-Ki Kim, Hyun-Young Kim, Seung-Hwan Lee, Mijeong Lee, Duck Choplated per well with lentivirus at the indicated viral copy number, with 10 μg/mL of vectofusin-1 (130-111-163, Miltenyi Biotec, Bergisch Gladbach, Germany) and 200 U/mL of IL-2 in their cognate complete medium.

(4) From byproduct to biotherapeutic: Comparative study of buffy coats and leukoreduction system chambers for NK cell-based immunotherapiesiScienceMarch 20, 2026Tietze M, Schuldt M, Wohsmann M, Hölig K, Hanenberg H, Tonn T, Eitler J, Rurik JG, Künzel SR.KG,Cat# 8043.1 Human Serum Albumin - Baxalta,Takeda GmbH,PZN 11128720 Vectofusin-1,Miltenyi Biotec,Cat# 130-111-163 Accutase,Biozol,Cat# BLD-423201 DMEM GlutaMAX,Fisher Scientific,Cat# 10566016 Fetal Bovine Serum

(5) Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapyMolecular OncologyMarch 14, 2026Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, et al.replaced with complete RPMI medium containing no FBS and supplemented with Vectofusin‐1 (cat. no.: 130‐111‐163; Miltenyi Biotec, Bergisch Gladbach, Germany) to enhance transduction efficiency. Lentiviral particles

(6) Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancerCancer CellMarch 5, 2026Marco Campisi, Tatsuya Osaki, Ian Dryg, Carla Stornante, Jacqueline Wolff, Jason Weirather, Nicholas Weaver, Mubin Tarannum, Ian Gillanders, Alan Bers, et al.1000 rcf, 32°C) in RP10 media, lentiviral particles and Vectofusin-1 (10 μg/mL, Miltenyi Biotec, Cat# 130-111-163). Cells were cultured in NK MACS media (Miltenyi Biotec Cat#, 130-114-429) supplemented with 5% human

(7) Transduction of Quiescent Human Hematopoietic Stem and Progenitor Cells Using Lentiviral Vectors and Virus‐Like ParticlesCurrent ProtocolsJanuary 27, 2026Denise Klatt, Christian BrendelCellGenix®, Cat# 20806–0500 Trypan blue (Gibco, cat. no. 15250061) Vectofusin-1 (Miltenyi, cat. no. 130–111-163) Lentiviral vector (see Basic Protocol 1) or virus-like particles (VLP; see Alternate Protocol) 12.5

(8) A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic CancerInternational Journal of Molecular SciencesJanuary 3, 2026Weiyang Jin, Mengying Wang, Jingwei Wang, Jinyi Fan, Jie Fang, Guanghua Yangwere transduced with lentiviral particles. The co-infective agent Vectofusin-1 (Miltenyi Biotec; Cat: 130-111-163, Shanghai, China) with lentiviral particles at a final concentration of 5 μg/mL, with a total volume

(9) Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xenograft miceNature communicationsOctober 8, 2025Liu F, Tarannum M, Zhao Y, Zhang YJ, Ham JD, Lei K, Qiang Y, Deng X, Nguyen M, Dinh K, et al.were transduced with the lentiviral vector in the presence of 10 µg/ml of Vectofusion-1 (Miltenyi #130-111-163) in the NK expansion media at an MOI of 10. After adding the virus, the cells were centrifuged at 1000

(10) Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapiesJ Transl MedAugust 19, 2025Belén Sierro-Martínez, Beatriz Guijarro-Albaladejo, Ricardo Fernández-Cisnal, Alfonso Rodríguez-Gil, Paola Hernández-Díaz, María de la Rosa-Garrido, Inmaculada Carrasco-Brocal, Maribel Lara-Chica, Virginia Escamilla-Gómez, Raquel Muñoz-García, et al.and 1 mg/mL (SIRION Biotech: SB-P-LV-101–01) and Vectofusin-1 10, 40, and 80 ug/mL (Miltenyi Biotec, 130–111-163) were added prior lentivirus and spinoculation following manufacturer’s instructions. Cell numbers and

(11) Cell type-specific delivery by modular envelope designNat CommunAugust 23, 2023Daniel Strebinger, Chris J. Frangieh, Mirco J. Friedrich, Guilhem Faure, Rhiannon K. Macrae, Feng ZhangPolybrene (Santa Cruz Biotechnology Cat. # sc-134220) or 10 µg/ml of vectofusin (Miltenyi Biotec, Cat. # 130-111-163) were added. Spinoculations were performed at 1500 × g for 90 min at 33 °C. For DIRECTED tropism, the

(12) Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinomaImmunologyJune 1, 2023Chen L, Liu S, Adah D, Sun Q, Liang Z, Ho M, Sun B.lentiviral particles containing the CAR gene at a multiplicity of infection of 5. And vectofusin-1 (Cat: 130111163, Miltenyi Biotec) was used to promote lentiviral transduction of NK. After 48 h, the expression of CAR

(13) CAR-T Cells with Phytohemagglutinin (PHA) Provide Anti-Cancer Capacity with Better Proliferation, Rejuvenated Effector Memory, and Reduced Exhausted T Cell FrequenciesVaccinesJanuary 31, 2023Gulden G, Sert B, Teymur T, Ay Y, Tiryaki NN, Mishra AK, Ovali E, Tarhan N, Tastan C.11082132001, 20 mg). Lentivirus transduction procedure, Vectofusin 1 (10 µg/mL) (Miltenyi Biotech, 130-111-163), and BX-795 hydrochloride (6 µM) (Millipore Sigma, Burlington, MA, USA, SML0694- 5MG) were inoculated

Be the First to Write a Review!

Vectofusin®-1 from Miltenyi Biotec

Miltenyi Biotec

Miltenyi Biotec

Citations (13)

Reviews

Vectofusin®-1 from Miltenyi Biotec

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map